Vifor Confident About Prospects For Pruritus Dialysis Drug Korsuva

Submissions Imminent In US and Europe

Vifor CEO Stefan Schulze tells Scrip that an expanded deal with Korsuva developer Cara Therapeutics means the US biotech will not have to invest in a commercial organization as the Swiss firm will mobilize its well-established sales force to launch the treatment for dialysis patients with CKD-associated pruritus.

Dialysis
About 40% of dialysis patients suffer from moderate to severe pruritus • Source: Shutterstock

Vifor Pharma Group ’s goal of becoming a world leader in nephrology has moved closer with the expansion of its pact with Cara Therapeutics, Inc. of the US which extends the Swiss group's rights to Korsuva, the partners' soon-to-be filed therapy for dialysis patients with chronic kidney disease-associated pruritus (CKD-aP).

The deal, which could be worth up to $440m follows an alliance inked in 2018 in which the joint venture...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.